EVX Ventures (originally established in 2015 as Esco Ventures and later rebranded in 2018) is a leading global life sciences venture builder, accelerator, and corporate venture capital arm. Headquartered in Singapore, the firm operates as a critical cross-border orchestration platform with key operational hubs and physical pipelines localized in Shanghai, China, and Boston, Massachusetts, USA.
EVX Ventures operates at the intersection of molecular therapeutics, gene editing, and biotechnology company incubation. Rather than acting as a passive financial investor, the firm functions primarily as a "venture builder"?actively collaborating with world-class academic scientists, research institutions, and early-stage entrepreneurs to architect, fund, and operationally scale biotechnology start-ups from the ground up. The company?s core mission is to commercialize disruptive biomedical platform technologies that redefine therapeutics for cancer, liver disease, cardiac pathologies, and severe immunological conditions.
Cross-Border Operational Ecosystem
A core differentiator of EVX Ventures is its dedicated bridge spanning the Singapore, Shanghai, and Boston biotech ecosystems. The firm leverages this geographic layout to optimize the drug development lifecycle for its portfolio companies:
* Shanghai Infrastructure: Serves as a major anchor for integrated research and development (R&D), chemistry, manufacturing, and controls (CMC) scaling, and clinical-grade manufacturing facilities (such as the advanced biopharma development complexes in Shanghai Waigaoqiao).
* Singapore & Boston Infrastructure: Deploys early-stage molecular discovery tools, academic joint ventures, global regulatory navigation, and deep institutional fundraising capabilities.
Technical Platforms and Co-Working Services
EVX Ventures delivers value to the global life sciences sector through specialized physical infrastructure, laboratory operational services, and entrepreneurial talent pipelines.
1. EVX Nexus (Life Sciences Launchpad)
EVX Nexus is the firm's flagship, 14,000-square-foot life sciences co-working laboratory and office incubator situated at Synapse within the Biopolis biomedical research hub in Singapore. It serves as an identical operational blueprint for the firm's global incubation facilities, designed to help early-stage startups bypass expensive capital expenditures and jumpstart physical R&D.
Plug-and-Play Shared Labs: Features a 6,650-square-foot fully integrated laboratory layout accommodating 50 to 60 scientists and entrepreneurs, alongside private lab suites ranging from 200 to 280 square feet.
State-of-the-Art Core Instrumentation: The facility provides direct access to high-value common laboratory equipment including:
Class II A2 Biological Safety Cabinets and chemical fume hoods.
Multi-temperature cold storage infrastructure ranging from ambient refrigeration to deep cryogenic freezers.
Turnkey Operational Services: EVX Nexus provides add-on fee-for-service packages to handle back-office operational friction for scientists, including initial laboratory setup compliance, global biological reagent procurement, and localized bookkeeping.
2. The Morphosis Fellowship Programme
Operating as a specialized human-capital accelerator supported by government and research entities (such as Enterprise Singapore and A*STAR), this program trains and equips aspiring bio-entrepreneurs. Fellowships focus on translating bench-scale scientific research into investable, corporate biotech structures, building an entrepreneurial pipeline that feeds directly into the EVX portfolio.
Portfolio Modalities and Therapeutic Product Lines
As a venture builder, the ultimate "products" of EVX Ventures are the highly specialized, clinically progressive biotechnology companies it creates and the therapeutic pipelines they develop. The firm's active co-founded portfolio focuses heavily on advanced genetic medicines and targeted cell therapies:
Carcell Biopharma Inc.: A prominent EVX-built company operating natively across Singapore and Shanghai. Carcell establishes its primary integrated R&D and manufacturing operations in Shanghai Waigaoqiao to develop next-generation cell and gene therapies. The company focuses on two lead technical platforms: engineered red blood cells optimized for precise immuno-modulation, and non-viral gene delivery mechanisms driven by custom lipid nanoparticles (LNPs).
Carmine Therapeutics: Pioneering a powerful new class of non-viral genetic medicines based on engineered red blood cell extracellular vesicles (RBCEVs). This platform technology enables the safe, repeatable delivery of large genetic payloads directly to targeted tissues without triggering the severe immune rejections commonly associated with traditional viral-vector delivery methods.
2. Advanced Monoclonal and Nanobody Design
AltruBio: A clinical-stage biopharmaceutical entity focusing on the design and execution of novel antibody therapeutics. The platform targets unique T-cell activation pathways to build long-acting treatments for immunological and severe inflammatory diseases with high unmet medical needs, such as steroid-refractory acute Graft-versus-Host Disease (GvHD).
Jotbody: Operating as a dedicated business-to-business (B2B) discovery partner, Jotbody utilizes a high-throughput platform to specialize in single-domain antibody (sdAb, commonly referred to as nanobody) discovery and production. The entity markets high-purity nanobody-based research reagents and custom diagnostic screening services to the global scientific community.
3. Targeted RNA and Gene Therapies
Lerna Biopharma: A preclinical-stage biopharmaceutical organization focused entirely on utilizing data science and advanced molecular design to develop innovative RNA therapeutics for patients suffering from chronic, hard-to-treat liver diseases.
Nuevocor: Focuses on restoring human cardiac function by developing adeno-associated virus (AAV) gene therapy vectors. The company utilizes a genetic modifier approach to deliver specialized therapeutic cargos engineered to treat genetically defined, presently incurable cardiac diseases and congestive heart failure.
Please note: This information is generated by AI. For legal use, verify with company sources.
